Equity moves for NeoGenomics (NASDAQ: NEO) CFO Jeffrey Sherman
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
NeoGenomics Chief Financial Officer Jeffrey Scott Sherman reported equity award activity, not open‑market trading. On February 21 and February 23, he converted restricted stock units into common stock in transactions coded as exercises or conversions. The filing also shows shares withheld and disposed of to cover tax obligations related to these RSU releases. After these transactions, he directly owned 220,009 shares of common stock, alongside multiple outstanding stock option, restricted stock unit, and performance stock unit awards that vest over future years.
Positive
- None.
Negative
- None.
Insider Trade Summary
57,693 shares exercised/converted
Mixed
14 txns
Insider
Sherman Jeffrey Scott
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 15,535 | $0.00 | -- |
| Exercise | Common Stock | 15,535 | $0.00 | -- |
| Tax Withholding | Common Stock | 3,783 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 42,158 | $0.00 | -- |
| Exercise | Common Stock | 42,158 | $0.00 | -- |
| Tax Withholding | Common Stock | 10,729 | $0.00 | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Performance Stock Unit | -- | -- | -- |
| holding | Restricted Stock Unit | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Unit — 15,536 shares (Direct);
Common Stock — 223,792 shares (Direct);
Stock Option (Right to Buy) — 249,169 shares (Direct);
Performance Stock Unit — 39,016 shares (Direct)
Footnotes (1)
- Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. This balance includes 434 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan. The shares were acquired in transactions exempt from Section 16b-3. Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. On February 21, 2025, Mr. Sherman was granted 126,476 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. Once vested, the shares of common stock are not subject to expiration. On February 23, 2024, Mr. Sherman was granted 46,606 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On December 5, 2022, Mr. Sherman was granted 249,169 stock options. The options vest ratably over four years with the first tranche vesting on December 7, 2023. On May 11, 2023, Mr. Sherman was granted 73,016 stock options. The options vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Mr. Sherman was granted 39,016 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. On May 11, 2023, Mr. Sherman was granted 39,016 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 58,524. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. On February 23, 2024, Mr. Sherman was granted 77,913 stock options. The options vest ratably over the first three anniversary dates of the grant date. On February 23, 2024, Mr. Sherman was granted 46,606 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 69,910. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. On February 21, 2025, Mr. Sherman was granted 214,900 stock options. The options vest ratably over the first three anniversary dates of the grant date.
FAQ
What insider transactions did NeoGenomics (NEO) CFO Jeffrey Sherman report?
Jeffrey Sherman reported converting restricted stock units into NeoGenomics common stock, plus related share dispositions to cover tax withholding. These were equity award exercises and tax payments, not open-market buys or sells, and left him with 220,009 directly held common shares.
What equity awards were highlighted for the NeoGenomics (NEO) CFO?
Footnotes describe grants of restricted stock units, performance stock units and stock options, including 214,900 stock options granted on February 21, 2025. These awards generally vest ratably over three or four years and, once vested, convert into common stock without expiration.
How are NeoGenomics (NEO) restricted stock units treated in this filing?
Each restricted stock unit equals one share of NeoGenomics common stock and converts into common stock upon vesting. The filing shows RSU conversions into shares, with some of those shares withheld and disposed of to satisfy associated tax withholding obligations at vesting.